The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 504-508

  Dai, Zhenhua ^a   Lakkis, Fadi G ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2;

CYTOKINE PRODUCTION; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; NEGATIVE FEEDBACK; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0032872565     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00008-4     Document Type: Review

References (61)

1. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science. 283:1999;680-682. This manuscript provides evidence that T cell costimulation via CD28 receptors enhances the signaling environment of the engaged TCR. This implies that what had been previously thought of as two distinct stimulatory pathways actually converge at the membrane level.
2. ••].
3. ••].
4. ••] demonstrate yet another immunostimulatory role for the CD40-CD40L pathway: the generation of CTLs. This provides further explanation for why blocking CD40-CD40L interaction is especially effective in preventing allograft rejection.
5. Grewal IS, Flavell RA CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 16:1998;111-135.
6. Gudmundsdottir H, Turka LA T cell costimulatory blockade: new therapies for transplant rejection. J Am Soc Nephrol. 10:1999;1356-1365.
7. Wekerle T, Sayegh MH, Hill J, Zhao Y, Chandraker A, Swenson KG, Zhao G, Sykes M Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 187:1998;2037-2044. This manuscript demonstrates that costimulation blockade combined with donor bone marrow transplantation is a very powerful strategy for achieving transplantation tolerance to solid organs. More importantly, the findings raise the possibility that costimulation blockade may obviate the need for depleting some of the host's bone marrow cells with toxic irradiation - traditionally required for successful engraftment of donor bone marrow cells.
8. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JHJ, Knechtle SJ CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 94:1997;8789-8794.
9. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NBet al. Humanized anti-CD154 monoclonal antibody treatment prevents acute renal allograft rejection in non-human primates. Nat Med. 5:1999;686-693. The authors report on long-term, rejection-free survival of renal allografts in nine rhesus monkeys treated with a humanized anti-CD40L antibody. They also provide preliminary evidence that the concomitant administration of calcineurin inhibitors may abrogate the beneficial effect of anti-CD40L.
10. Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest. 101:1998;2309-2318. This manuscript demonstrates that CTLA-4-Ig slows the progression of chronic renal allograft rejection in rats, even if it is administered after the onset of chronic rejection.
11. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH Blockade of T-cell costimulation prevents development of experimental chronic allograft rejection. Proc Natl Acad Sci USA. 93:1996;12072-12075.
12. - T lymphocytes by 4-1BB ligand. J Immunol. 158:1997;551-559.
13. Wu Y, Shou Q, Zheng P, Liu Y CD28-independent induction of T helper cells and immunoglobulin class switching requires costimulation by heat-stable antigen. J Exp Med. 187:1998;1151-1156.
14. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 397:1999;263-266.
15. Steiger B, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom JB IL-2 knockout recipient mice reject islet cell allografts. J Immunol. 155:1995;489-498.
16. -/- mice repeatedly stimulated with alloantigen.
17. Nickerson P, Zheng X, Steiger J, Steele AW, Steurer W, Roy-Chaudhury P, Muller W, Strom TB Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transplant Immunol. 4:1996;81-85.
18. Lakkis FG, Konieczny BT, Saleem S, Baddoura FK, Linsley PS, Alexander DZ, Lowry RP, Pearson TC, Larsen CP Blocking the CD28-B7 T cell costimulation pathway induces long-term cardiac allograft acceptance in the absence of interleukin-4. J Immunol. 158:1997;2443-2448.
19. Li XC, Roy-Chaudhury P, Hancock WW, Manfro R, Zand MS, Li Y, Zhen XX, Nickerson PW, Steiger J, Malek TR, Strom TB IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J Immunol. 160:1998;890-896.
20. Saleem S, Konieczny BT, Lowry RP, Baddoura FK, Lakkis FG Acute rejection of vascularized heart allografts in the absence of IFNγ Transplantation. 62:1996;1908-1911.
21. Steiger JU, Nickerson PW, Hermle M, Thiel G, Heim MH IFNγ receptor signaling is not required in the effector phase of the alloimmune response. Transplantation. 65:1998;1649-1652.
22. Picotti JR, Chan SY, Goodman RE, Magram J, Eichwald EJ, Bishop DK IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol. 157:1996;1951-1957.
23. Picotti JR, Li K, Chan SY, Ferrante J, Magram J, Eichwald EJ, Bishop DK Alloantigen-reactive Th1 development in IL-12-deficient mice. J Immunol. 160:1998;1132-1138.
24. Yang Y-G, Dey B, Sergio JJ, Pearson DA, Sykes M Donor-derived interferon-γ is required for inhibition of acute GVHD by interleukin 12. J Clin Invest. 102:1998;2126-2135.
25. Ring GH, Saleem S, Dai Z, Hassan AT, Konieczny BT, Baddoura FK, Lakkis FG Interferon-γ is necessary for initiating the acute rejection of major histocompatibility complex class II-disparate skin allografts. Transplantation. 67:1999;1362-1365. Unlike the redundancy observed with other cytokines, IFN-γ is shown in this manuscript to be absolutely essential for the rejection of class-II-mismatched skin grafts.
26. Rosenberg AS, Finbloom DS, Maniero TG, Van der Meide PH, Singer A Specific prolongation of MHC class 2 disparate skin allografts by in vivo administration of anti-IFN-γ monoclonal antibody. J Immunol. 144:1990;4648-4650.
27. Goes N, Sims T, Urmson J, Vincent D, Ramassar V, Halloran PF Disturbed MHC regulation in interferon-γ knockout mouse. J Immunol. 155:1995;4559-4566.
28. Goes N, Urmson J, Hobart M, Halloran PF The unique role of interferon-γ in the regulation of MHC expression on arterial endothelium. Transplantation. 62:1996;1889-1894.
29. Picotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation. 63:1997;619-624.
30. Mueller R, Davies JD, Krahl T, Sarvetnick N IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J Immunol. 159:1997;1599-1603.
31. Takeuchi T, Ueki T, Sunaga S, Ikuta K, Sasaki Y, Li B, Moriyama M, Miyazaki J-I, Kawabe K Murine interleukin 4 transgenic heart allograft survival prolonged with down-regulation of the TH1 cytokine mRNA in grafts. Transplantation. 64:1997;152-157.
32. Zheng X, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol. 154:1995;5590-5600.
33. Matesic D, Valujskikh A, Pearlman E, Higgins AW, Gilliam AC, Heeger PS Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells. J Immunol. 161:1998;5236-5244.
34. Mottram PL, Raisanen-Sokolowski A, Glysing-Jensen T, Stein-Oakley AN, Russell ME Cardiac allografts from IL-4 knockout recipients: assessment of transplant arteriosclerosis and peripheral tolerance. J Immunol. 161:1998;602-609.
35. Hall BM, Fava L, Chen J, Plain KM, Boyd RA, Spicer ST, Berger MF Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ supressor T cells that are not dependent on IL-4. J Immunol. 161:1998;5147-5156.
36. Bushell A, Niimi M, Morris PJ, Wood KJ Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. J Immunol. 162:1999;1359-1366.
37. Davies JD, Martin G, Phillips J, Marshall SE, Cobbold SP, Waldmann H T cell regulation in adult transplantation tolerance. J Immunol. 157:1996;529-533.
38. Valujskikh A, Heeger PS Mechanisms of tolerance to a transgenic minor transplantation antigen [abstract]. Transplantation. 67:1999;241.
39. Gao Q, Chen N, Rouse TM, Field EH The role of IL-4 in the induction phase of allogeneic neonatal tolerance. Transplantation. 62:1996;1847-1854.
40. Chen N, Gao Q, Field EH Prevention of TH1 responses is critical for tolerance. Transplantation. 61:1996;1076-1083.
41. Punch JD, Tono T, Qin L, Bishop DK, Bromberg JS Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: evidence for an IL-4 requirement. J Immunol. 161:1998;1156-1162.
42. Sirak JH, Orosz CG, Roopenian DC, Wakely E, VanBuskirk AM Cardiac allograft tolerance: failure to develop in interleukin-4-deficient mice correlates with unusual allosensitization patterns. Transplantation. 65:1998;1352-1356.
43. Li XC, Zand MS, Li Y, Zheng XX, Strom TB On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol. 161:1998;2241-2247. Unlike allografts fully mismatched at the MHC, the rejection or acceptance of organs matched at the MHC but mismatched at minor histocompatibility antigens appears to conform to the prediction of the Th1/Th2 paradigm.
44. ••] demonstrate that endogenous IFN-γ facilitates rather than hinders the induction of allograft acceptance. The regulatory role of IFN-γ could be attributed in part to its antiproliferative actions.
45. ••].
46. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart T Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science. 259:1993;1739-1742.
47. Hassan AT, Dai Z, Konieczny BT, Ring GH, Baddoura FK, Abou-Dahab LH, El-Sayed AA, Lakkis FG Regulation of alloantigen-mediated T-cell proliferation by endogenous interferon-γ: implications for long-term allograft acceptance. Transplantation. 68:1999;124-129.
48. Lenardo MJ Interleukin-2 programs mouse alpha/beta T lymphocytes for apoptosis. Nature. 353:1991;858-861.
49. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol. 25:1995;3053-3059.
50. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75:1993;253-261.
51. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyuma T, Schmitts R, Simard JJL, Ohashi PS, Griesser Het al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β Science. 268:1995;1472-1476.
52. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 3:1995;521-530.
53. Van-Parijs L, Biuckians A, Ibragimov A, Alt FW, Willerford DM, Abbas AK Functional responses and apoptosis of CD25 (IL-2Rα)-deficient T cells expressing a transgenic antigen receptor. J Immunol. 158:1997;3738-3745.
54. + T cells. Conversely, transfecting FLIP cDNA inhibits the activation-induced apoptosis of Jurkat T cells.
55. Van Parijs L, Abbas AK Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:1998;243-248.
56. Krummel MF, Allison JP CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 183:1996;2533-2540.
57. Walunas TL, Bakker CY, Bluestone JA CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 183:1996;2541-2550.
58. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK Induction of peripheral tolerance in vivo requires CTLA-4 engagement. Immunity. 6:1997;411-417.
59. Zheng XX, Markees TG, Hancock WW, Li Y, Greiner DL, Li XC, Mordes JP, Sayegh MH, Rossini AA, Strom TB CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol. 162:1999;4983-4990. This manuscript builds on work done in [56] to demonstrate that blocking interactions between B7 and CTLA-4 hinders the induction of tolerance to pancreatic islet cells.
60. Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre M-L Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med. 188:1998;199-204.
61. Larsen C, Elwood E, Alexander D, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PSet al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:1996;434-438.